secwatch.observer — SEC 8-K summary
======================================

Issuer:     Climb Bio, Inc. (CLYM)
CIK:        0001768446
Form:       8-K
Filed at:   2022-11-14T23:59:59+00:00
Accession:  0000950170-22-024621
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Eliem Therapeutics Q3 net loss $9.7M, cash $129.6M; ETX-155 Phase 2a MDD trial to start Q1 2023
--------------------------------------------------------------------------------

- Net loss of $9.7M for Q3 2022 (vs. $9.6M Q3 2021); R&D expenses $4.3M, G&A $4.5M.
- Cash and marketable securities $129.6M as of Sep 30, 2022; cash runway expected to fund operations into 2025.
- ETX-155 Phase 2a MDD trial to initiate in Q1 2023 with 60-mg dose; topline data expected H2 2024.
- Kv7.2/3 program: IND-enabling safety studies for two pre-candidates expected Q1 2023; Phase 1 studies planned H1 2024.
- Phase 1 PK trial completed; selected 60-mg dose over 75-mg due to marginal additional benefit.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1768446/000095017022024621/0000950170-22-024621-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1768446/000095017022024621/elym-20221114.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-024621

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer